BOLT vs CADL

Bolt Biotherapeutics, Inc. vs Candel Therapeutics, Inc. — Valuation Comparison 2026

BOLT

Biotechnology
Bolt Biotherapeutics, Inc.
Quality
5.9
out of 10
Value Trap
30
LOW
Price
$5.30
Last close
Models
9/13
Active
VS

CADL

Biotechnology
Candel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
38
LOW
Price
$8.09
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType BOLT Fair ValueBOLT Upside CADL Fair ValueCADL Upside
Bayesian DCF Intrinsic $0.54 -88.5% $3.35 -58.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $17.21 +224.6% $0.10 -98.5%
Dynamic NAV Asset-Based $23.97 +352.2% $2.44 -69.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BOLT vs CADL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BOLT vs CADL — Which Stock Is More Undervalued?

BOLT scores higher with a 5.9/10 quality rating vs CADL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bolt Biotherapeutics, Inc. (BOLT) and Candel Therapeutics, Inc. (CADL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BOLT currently trades at $5.30 with a QOC of 5.9/10, while CADL trades at $8.09 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).